Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
Current anti-VEGF therapies for colorectal cancer (CRC) provide limited survival benefit, as tumors rapidly develop resistance to these agents. Here, we have uncovered an immunosuppressive role for nonclassical Ly6Clo monocytes that mediates resistance to anti-VEGFR2 treatment. We found that the chemokine CX3CL1 was upregulated in both human and murine tumors following VEGF signaling blockade, resulting in recruitment of CX3CR1+Ly6Clo monocytes into the tumor. We also found that treatment with VEGFA reduced expression of CX3CL1 in endothelial cells in vitro. Intravital microscopy revealed that CX3CR1 is critical for Ly6Clo monocyte transmigration across the endothelium in murine CRC tumors. Moreover, Ly6Clo monocytes recruit Ly6G+ neutrophils via CXCL5 and produce IL-10, which inhibits adaptive immunity. Preventing Ly6Clo monocyte or Ly6G+ neutrophil infiltration into tumors enhanced inhibition of tumor growth with anti-VEGFR2 therapy. Furthermore, a gene therapy using a nanoparticle formulated with an siRNA against CX3CL1 reduced Ly6Clo monocyte recruitment and improved outcome of anti-VEGFR2 therapy in mouse CRCs. Our study unveils an immunosuppressive function of Ly6Clo monocytes that, to our knowledge, has yet to be reported in any context. We also reveal molecular mechanisms underlying antiangiogenic treatment resistance, suggesting potential immunomodulatory strategies to enhance the long-term clinical outcome of anti-VEGF therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that an optimum level of VEGF and ANG2 blockade will be needed to alleviate immunosuppression in the TME”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“preclinical evidence indicates that high-dose and/or long-term antiangiogenic therapy causes massive vessel pruning and increases immunosuppression in tumour models37–40”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“High doses of anti-VEGF agents can also lead to increased deposition of extracellular matrix that, together with hypoxia, can promote the infiltration of immunosuppressive and/or pro-tumour immune cells, such as monocytic and granulocytic MDSCs37–39”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“emerging data suggest that immunosuppression, in turn, contributes to resistance to antiangiogenesis treatments37–39,41”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“In mouse models of CRC, high-dose anti-VEGF treatment can also result in the recruitment of immunosuppressive, nonclassical, lymphocyte antigen 6C (Ly6C)low monocytes that also confer resistance to anti-VEGF therapy, thus setting up a vicious cycle38,39”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467
Self-citationAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544 · cited 1×
“These cells display a high level of CX3CR1, while Ly6Chi monocytes and Ly6G+ neutrophils (hereafter referred to as neutrophils) express CCR2 and CXCR2, respectively (25, 39, 44) (Supplemental Figure 2B).”
BackgroundBlood Monocytes Consist of Two Principal Subsets with Distinct Migratory Properties
Geissmann, F., Jung, S., & Littman, D. R. (2003) · Immunity · doi:10.1016/s1074-7613(03)00174-2 · Cited by 3,391
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874 · cited 1×
“, CX3CR1 on Ly6Clo monocytes, CCR2 on Ly6Chi monocytes) (32, 59) (Supplemental Figure 2B).”
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Cited by
VEGF in signaling and disease: beyond discovery and development
Apte, R. S., Chen, D. S., & Ferrara, N. (2019) · Cell · doi:10.1016/j.cell.2019.01.021 · Cited by 2,721
“, 2017) or inhibiting adaptive immunity (Jung et al., 2017).”
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationCassetta, L., Fragkogianni, S., Sims, A. H., Swierczak, A., Forrester, L. M., Zhang, H., Soong, D. Y. H., Cotechini, T., Anur, P., Lin, E. Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.009 · Cited by 920
Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-00500-y · Cited by 688
Consensus guidelines for the use and interpretation of angiogenesis assays
Nowak-Sliwinska, P., Alitalo, K., Allen, E., Anisimov, A., Aplin, A. C., Auerbach, R., Augustin, H. G., Bates, D. O., van Beijnum, J. R., Bender, R. H. F., et al. (2018) · Angiogenesis · doi:10.1007/s10456-018-9613-x · Cited by 590
Self-citationMonocyte heterogeneity and functions in cancer
Olingy, C. E., Dinh, H. Q., & Hedrick, C. C. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.4ri0818-311r · Cited by 579
Improving immune–vascular crosstalk for cancer immunotherapy
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530
Self-citationYang, Q., Guo, N., Zhou, Y., Chen, J., Wei, Q., & Han, M. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.04.004 · Cited by 471
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Hegde, P. S., Wallin, J. J., & Mancao, C. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.002 · Cited by 453
Chen, I. X., Chauhan, V. P., Posada, J., Ng, M. R., Wu, M. W., Adstamongkonkul, P., Huang, P., Lindeman, N., Langer, R., & Jain, R. K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815515116 · Cited by 406
Self-citationFlores-Toro, J. A., Luo, D., Gopinath, A., Sarkisian, M. R., Campbell, J. J., Charo, I. F., Singh, R., Schall, T. J., Datta, M., Jain, R. K., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910856117 · Cited by 334
Self-citationTargeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 319
Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies
Kumari, N., & Choi, S. H. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02272-x · Cited by 315
Tailoring Nanomaterials for Targeting Tumor‐Associated Macrophages
Ovais, M., Guo, M., & Chen, C. (2019) · Advanced Materials · doi:10.1002/adma.201808303 · Cited by 298
Macrophages: The Road Less Traveled, Changing Anticancer Therapy
Guerriero, J. L. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.03.006 · Cited by 293
How chemokines organize the tumour microenvironment
Mempel, T. R., Lill, J. K., & Altenburger, L. M. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-023-00635-w · Cited by 281
Wang, D., Yang, L., Yu, W., Wu, Q., Lian, J., Li, F., Liu, S., Li, A., He, Z., Liu, J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0701-2 · Cited by 234
The Tumor Vascular Endothelium as Decision Maker in Cancer Therapy
Klein, D. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00367 · Cited by 196
“One important physiological function of normal endothelial cells is quiescence of the inflammatory response and thus, participation in immune surveillance (21, 22).”
BackgroundChoi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
Self-citationNew insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects
Huang, M., Lin, Y., Wang, C., Deng, L., Chen, M., Assaraf, Y. G., Chen, Z.-S., Ye, W., & Zhang, D. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100849 · Cited by 173
Myeloid cell heterogeneity in cancer: not a single cell alike
Kiss, M., Van Gassen, S., Movahedi, K., Saeys, Y., & Laoui, D. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.02.008 · Cited by 159
Sullivan, K. M., Jiang, X., Guha, P., Lausted, C. G., Carter, J. A., Hsu, C. L., Labadie, K. P., Kohli, K., Kenerson, H. L., Daniel, S. K., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-325808 · Cited by 154
Jung, K., Heishi, T., Incio, J., Huang, Y., Beech, E. Y., Pinter, M., Ho, W. W., Kawaguchi, K., Rahbari, N. N., Chung, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710754114 · Cited by 138
Self-citationDong, X., Ren, J. P., Amoozgar, Z., Lee, S., Datta, M., Roberge, S., Duquette, M. A., Fukumura, D., & Jain, R. K. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005583 · Cited by 151
Self-citationVascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response
Geindreau, M., Ghiringhelli, F., & Bruchard, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094871 · Cited by 135
Khan, O. F., Kowalski, P. S., Doloff, J. C., Tsosie, J. K., Bakthavatchalu, V., Winn, C. B., Haupt, J., Jamiel, M., Langer, R., & Anderson, D. G. (2018) · Science Advances · doi:10.1126/sciadv.aar8409 · Cited by 119
Self-citationVascular Normalization: A New Window Opened for Cancer Therapies
Yang, T., Xiao, H., Liu, X., Wang, Z., Zhang, Q., Wei, N., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719836 · Cited by 141
Immune regulation by monocytes
Murray, P. J. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.12.005 · Cited by 132
The roles of the COX2/PGE2/EP axis in therapeutic resistance
Tong, D., Liu, Q., Wang, L.-A., Xie, Q., Pang, J., Huang, Y., Wang, L., Liu, G., Zhang, D., Lan, W., et al. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9752-y · Cited by 111
Mpekris, F., Panagi, M., Voutouri, C., Martin, J. D., Samuel, R., Takahashi, S., Gotohda, N., Suzuki, T., Papageorgis, P., Demetriou, P., et al. (2021) · Advanced Science · doi:10.1002/advs.202001917 · Cited by 102
Liu, Y., Zhou, J., Li, Q., Li, L., Jia, Y., Geng, F., Zhou, J., & Yin, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.019 · Cited by 102
Ho, W. W., Gomes-Santos, I. L., Aoki, S., Datta, M., Kawaguchi, K., Talele, N. P., Roberge, S., Ren, J. P., Liu, H., Chen, I. X., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105323118 · Cited by 102
Self-citationTherapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies
Comunanza, V., & Bussolino, F. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00101 · Cited by 111
Missiaen, R., Mazzone, M., & Bergers, G. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.06.002 · Cited by 94
Cancer-Associated Angiogenesis: The Endothelial Cell as a Checkpoint for Immunological Patrolling
Solimando, A. G., Summa, S. D., Vacca, A., & Ribatti, D. (2020) · Cancers · doi:10.3390/cancers12113380 · Cited by 98
Kim, M., Shin, M., Zhao, Y., Ghosh, M., & Son, Y. (2024) · Small Science · doi:10.1002/smsc.202400280 · Cited by 97
Smit, M. J., Schlecht‐Louf, G., Neves, M., van den Bor, J., Penela, P., Siderius, M. H., Bachelerie, F., & Mayor, F. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023340 · Cited by 96
The Good, the Bad, and the Ugly: Neutrophils, Angiogenesis, and Cancer
Ozel, I., Duerig, I., Domnich, M., Lang, S., Pylaeva, E., & Jablonska, J. (2022) · Cancers · doi:10.3390/cancers14030536 · Cited by 86
Novel Drugs with High Efficacy against Tumor Angiogenesis
Qi, S., Deng, S., Lian, Z., & Yu, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136934 · Cited by 99
TGFβ signaling pathways in human health and disease
Chen, P., Qin, L., & Simons, M. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1113061 · Cited by 99
Tumour-infiltrating neutrophils counteract anti-VEGF therapy in metastatic colorectal cancer
Schiffmann, L. M., Fritsch, M., Gebauer, F., Günther, S. D., Stair, N. R., Seeger, J. M., Thangarajah, F., Dieplinger, G., Bludau, M., Alakus, H., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0198-3 · Cited by 79
Maimon, A., Levi-Yahid, V., Ben‐Meir, K., Halpern, A., Talmi, Z., Priya, S., Mizraji, G., Mistriel-Zerbib, S., Berger, M., Baniyash, M., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci126089 · Cited by 89
Li, S., Chen, J. Y., & Sun, Z. (2021) · 癌症:英文版 · doi:10.1002/cac2.12183 · Cited by 87
Lin, Y., Tan, C., Chen, C.-W., Ou, D., Cheng, A., & Hsu, C. (2018) · Seminars in Liver Disease · doi:10.1055/s-0038-1673621 · Cited by 84
Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis
Mazzone, M., & Bergers, G. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114721 · Cited by 74
Functionalized Nanoparticles Targeting Tumor-Associated Macrophages as Cancer Therapy
He, Y., Júnior, R. F. D. A., Cruz, L. J., & Eich, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13101670 · Cited by 70
Nahrendorf, W., Ivens, A. C., & Spence, P. J. (2021) · eLife · doi:10.7554/elife.63838 · Cited by 64
Elwan, A., Abdallah, A. E., Mahdy, H. A., Dahab, M. A., Taghour, M. S., Elkaeed, E. B., Mehany, A. B. M., Nabeeh, A., Adel, M., Alsfouk, A. A., et al. (2022) · Molecules · doi:10.3390/molecules27155047 · Cited by 62
Jeong, J., Suh, Y., & Jung, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01817 · Cited by 60
Self-citationNanomedicine-based cancer immunotherapies developed by reprogramming tumor-associated macrophages
Li, X., Guo, X., Ling, J., Tang, Z., Huang, G., He, L., & Chen, T. (2021) · Nanoscale · doi:10.1039/d0nr08050k · Cited by 61
Hyeon, D. Y., Nam, D., Han, Y., Kim, D. K., Kim, G., Kim, D., Bae, J., Back, S., Mun, D., Madar, I. H., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00479-7 · Cited by 59
Self-citationTumor Immunosurveillance and Immunotherapies: A Fresh Look from Intravital Imaging
Boulch, M., Grandjean, C. L., Cazaux, M., & Bousso, P. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.09.002 · Cited by 53
Abdallah, A. E., Mabrouk, R. R., Elnagar, M. R., Farrag, A. M., Kalaba, M. H., Sharaf, M. H., El-Fakharany, E. M., Bakhotmah, D. A., Elkaeed, E. B., & Ward, M. M. S. A. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s344750 · Cited by 52
A bi-directional dialog between vascular cells and monocytes/macrophages regulates tumor progression
Delprat, V., & Michiels, C. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09958-2 · Cited by 54
Park, J. A., Wang, L., & Cheung, N. V. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01156-5 · Cited by 52
Nanoparticle-based immunoengineering strategies for enhancing cancer immunotherapy
Dang, B.-T. N., Kwon, T. K., Lee, S., Jeong, J., & Yook, S. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.12.007 · Cited by 55
Getting TANned: How the tumor microenvironment drives neutrophil recruitment
SenGupta, S., Subramanian, B. C., & Parent, C. A. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ri0718-282r · Cited by 51
Zheng, J., Jiang, J., Pu, Y., Xu, T., Sun, J., Zhang, Q., He, L., & Liang, X. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1248421 · Cited by 55
Choi, Y., Kim, S. A., Jung, H., Kim, Y. K., Kim, S., Kim, J., Kim, J., Lee, Y., Jo, M. K., Woo, J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008864 · Cited by 60
Bridging angiogenesis and immune evasion in the hypoxic tumor microenvironment
Schito, L. (2018) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00209.2018 · Cited by 52
Nanoparticle delivery in vivo: A fresh look from intravital imaging
Lin, Q., Fathi, P., & Chen, X. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102958 · Cited by 48
“Endothelial cellsMonocytes (CX3CR1Ly-6C) [19, 20]”
BackgroundInfluentialPrat, M., Naour, A. L., Coulson, K., Lemée, F., Leray, H., Jacquemin, G., Rahabi, M. C., Lemaitre, L., Authier, H., Ferron, G., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000472 · Cited by 51
Hypoxia: Turning vessels into vassals of cancer immunotolerance
Schito, L., & Rey, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.015 · Cited by 49
Endothelial cells in colorectal cancer
Chen, W., Jiang, J., Yu, X., Xia, W.-J., Yu, P.-X., Wang, K., Zhao, Z., & Chen, Z. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i11.946 · Cited by 47
A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy
Duru, G., van Egmond, M., & Heemskerk, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584723 · Cited by 48
Ishaqat, A., & Herrmann, A. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c08484 · Cited by 43
Immune Suppression Mediated by STAT4 Deficiency Promotes Lymphatic Metastasis in HNSCC
Anderson, K., Ryan, N. M., Volpedo, G., Varikuti, S., Satoskar, A. R., & Oghumu, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03095 · Cited by 43
Mannose-modified hyaluronic acid nanocapsules for the targeting of tumor-associated macrophages
Fernández‐Mariño, I., Anfray, C., Crecente‐Campo, J., Maeda, A., Ummarino, A., Teijeiro-Valiño, C., Blanco-Martínez, D., Mpambani, F., Poul, L., Devallière, J., et al. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-022-01265-9 · Cited by 42
Recent advances in intravital microscopy for investigation of dynamic cellular behavior in vivo
Choo, Y. W., Jeong, J., & Jung, K. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.7.069 · Cited by 41
Self-citationPolymersomes with splenic avidity target red pulp myeloid cells for cancer immunotherapy
Wauters, A. C., Scheerstra, J. F., van Leent, M. M. T., Teunissen, A. J. P., Priem, B., Beldman, T. J., Rother, N., Duivenvoorden, R., Prévot, G., Munitz, J., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01727-w · Cited by 49
Albakri, M. M., Veliz, F. A., Fiering, S., Steinmetz, N. F., & Sieg, S. F. (2019) · Immunology · doi:10.1111/imm.13135 · Cited by 37
Mennitto, A., Huber, V., Ratta, R., Sepe, P., de Braud, F., Procopio, G., Guadalupi, V., Claps, M., Stellato, M., Daveri, E., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040930 · Cited by 37
Use of Nanoformulation to Target Macrophages for Disease Treatment
Liu, X., Xie, X., Jiang, J., Lin, M. J., Zheng, E., Qiu, W., Yeung, I., Zhu, M., Li, Q., Xia, T., et al. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202104487 · Cited by 38
Tracking Monocytes and Macrophages in Tumors With Live Imaging
Laviron, M., Combadière, C., & Boissonnas, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01201 · Cited by 39
Pi, L., Fu, C., Lu, Y., Zhou, J., Jorgensen, M., Shenoy, V., Lipson, K. E., Scott, E. W., & Bryant, A. J. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00138 · Cited by 34
Zhang, Z., Yang, C., Li, L., Zhu, Y., Su, K., Zhai, L., Wang, Z., & Huang, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.699478 · Cited by 46
Jung, M. K., Aibaidula, A., Brown, D. A., Himes, B. T., Garcia, L. M. C., & Parney, I. F. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac017 · Cited by 45
Zhang, X., Wang, S., Nan, Y., Fan, J., Chen, W., Luan, J., Wang, Y., Liang, Y., Li, S., Tian, W., et al. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9069-3 · Cited by 34
Xiang, X., Wang, K., Zhang, H., Mou, H., Shi, Z., Tao, Y., Song, H., Lian, Z., Wang, S., Lu, D., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0627 · Cited by 39
Roberts, M. E., Barvalia, M., Silva, J. A. F. D., Cederberg, R. A., Chu, W. N., Wong, A., Tai, D. C., Chen, S., Matos, I., Priatel, J. J., et al. (2020) · Circulation Research · doi:10.1161/circresaha.119.315708 · Cited by 31
Wen, S., Chen, N., Hu, Y., Huang, L., Peng, J., Yang, M., Shen, X., Song, Y., & Xu, L. (2021) · Cancer Medicine · doi:10.1002/cam4.3773 · Cited by 30
Lung Macrophages: Multifunctional Regulator Cells for Metastatic Cells
Mukaida, N., Nosaka, T., Nakamoto, Y., & Baba, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010116 · Cited by 29
Tumor-specific interendothelial adhesion mediated by FLRT2 facilitates cancer aggressiveness
Ando, T., Tai-Nagara, I., Sugiura, Y., Kusumoto, D., Okabayashi, K., Kido, Y., Sato, K., Saya, H., Navankasattusas, S., Li, D. Y., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153626 · Cited by 29
PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
Bocanegra, A., Blanco, E., Fernández-Hinojal, G., Arasanz, H., Chocarro, L., Zuazo, M., Morente, P., Vera, R., Escors, D., & Kochan, G. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165918 · Cited by 25
NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer
Dong, C., Yin, F., Zhu, D., Cai, X., Chen, C., & Liu, X. (2020) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29670 · Cited by 31
Qi, Y., Song, Y., Cai, M., Li, J., Yu, Z., Li, Y., Huang, J., Jiang, Y., Peng, C., Jiang, B., et al. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17678 · Cited by 22
Reticker-Flynn, N. E., & Engleman, E. G. (2020) · eLife · doi:10.7554/elife.53839 · Cited by 26
Qiu, Z., Ji, J., Xu, Y., Zhu, Y., Gao, C., Wang, G., Li, C., Zhang, Y., Zhao, J., Wang, C., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02197-w · Cited by 24
Nonclassical Monocytes Are Prone to Migrate Into Tumor in Diffuse Large B-Cell Lymphoma
Gallou, S. L., Lhomme, F., Irish, J. M., Mingam, A., Pangault, C., Monvoisin, C., Ferrant, J., Azzaoui, I., Delphine Rossille, A., Bouabdallah, K. K., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.755623 · Cited by 22
Cancer Immunotherapy: Targeting Tumor-Associated Macrophages by Gene Silencing
Zins, K., & Abraham, D. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0290-4_17 · Cited by 24
Strategies to Overcome Hurdles in Cancer Immunotherapy
Kim, J. H., Lee, B. J., Moon, S., Lee, H., Lee, J., Kim, B., Jung, K., Seo, H., & Chung, Y. (2024) · Biomaterials Research · doi:10.34133/bmr.0080 · Cited by 21
Self-citationNon-classical monocytes in tissue injury and cancer
Bharat, A., McQuattie‐Pimentel, A. C., & Budinger, G. R. S. (2017) · Oncotarget · doi:10.18632/oncotarget.22584 · Cited by 16
Chen, J.-S., Hsieh, Y.-C., Chou, C.-H., Wu, Y., Yang, M.-H., Chu, S.-H., Chao, Y.-S., & Chen, C.-N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810677 · Cited by 19
Yousef, R. G., Elwan, A., Abdallah, A. E., Elkady, H., Mehany, A. B. M., Abo-Saif, M. A., Radwan, M. M., ElSohly, M. A., Ibrahim, I. M., Elkady, M. A., et al. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.137753 · Cited by 17
Muteeb, G., Khafaga, D. S. R., El-Morsy, M. T., Farhan, M., Aatif, M., & Hosney, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e37217 · Cited by 17
Lee, J. H., Kang, Y. K., Oh, E., Jeong, J., Im, S. H., Kim, D. K., Lee, H., Kim, S., Jung, K., & Chung, H. J. (2021) · Chemistry of Materials · doi:10.1021/acs.chemmater.1c02844 · Cited by 16
Self-citationGuglietta, S., & Krieg, C. (2022) · Blood Reviews · doi:10.1016/j.blre.2022.101012 · Cited by 20
Dickerson, L. K., Carter, J. A., Kohli, K., & Pillarisetty, V. G. (2023) · Gut · doi:10.1136/gutjnl-2023-329650 · Cited by 19
Li, Y., Wang, K., Zhao, E., Li, B., Li, S., Dong, X., Ling, Y., & Yang, H. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610245 · Cited by 13
Metadata
- Authors
- Jung, K., Heishi, T., Khan, O. F., Kowalski, P. S., Incio, J., Rahbari, N. N., Chung, E., Clark, J. W., Willett, C. G., Luster, A. D., Yun, S. H., Langer, R., Anderson, D. G., Padera, T. P., Jain, R. K., & Fukumura, D.
- Affiliations
- Harvard University (US)
- Koch Institute for Integrative Cancer Research At MIT (US)
- Duke Medical Center (US)
- Harvard–MIT Division of Health Sciences and Technology (US)
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2017-07-10
- Volume
- 127
- Issue
- 8
- Pages
- 3039-3051
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5531423
- OpenAlex
- W2726768474
- Cited by
- 164
- References
- 75
- Citations by year
- 2026: 10 · 2025: 10 · 2024: 13 · 2023: 10 · 2022: 28 · 2021: 26 · 2020: 25 · 2019: 20 · 2018: 16 · 2017: 6
- FWCI
- 8.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- National Institutes of Health (NIH DP2, W81XWH, 1dp2od008780-01, CA126642, CA080124)
- Harvard School of Engineering and Applied Sciences
- National Cancer Institute (CA096915, W81XWH-10-1-0016, R01CA096915, P01CA080124, R00CA137167, R01CA126642, R35CA197743, R01CA208205, R01CA204028)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK043351)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- fractalkine, CX3CR1, anti-VEGF therapy resistance, colorectal cancer, immunosuppression, neutrophil recruitment, CXCL5, IL-10, endothelial cells, monocyte transmigration, siRNA gene therapy, nanoparticle delivery, tumor microenvironment
- MeSH terms
- Intravital Microscopy, CX3C Chemokine Receptor 1, Animals, Antibodies, Monoclonal, Antigens, Ly, Antineoplastic Agents, Humans, Immunosuppression Therapy, Male, Mice, Inbred BALB C, Mice, Inbred C57BL, Monocytes, Neoplasms, Neutrophils, Up-Regulation, Drug Resistance, Neoplasm, Receptors, Chemokine, RNA, Small Interfering, Vascular Endothelial Growth Factor Receptor-2, Cell Line, Tumor, Mice, Nanoparticles, Chemokine CX3CL1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.